Autoimmune Hemolytic Anemia (AIHA) Resource Center

Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder resulting in the production of antibodies directed against red blood cell antigens, causing shortened erythrocyte survival. The disorder is an acquired hemolysis, and can be idiopathic or secondary to other autoimmune disorders, malignancies, or infections. Building on the recommendations that emerged from the First International Consensus Meeting on AIHA in 2019, FWGBD will provide web-based resources that focus on optimal treatment and management recommendations for patients with AIHA; bolster knowledge of medical complications that patients with AIHA may have; and provide cross-functional provider team management of medical complications for patients with AIHA.

These resources have been gathered in an effort to support healthcare providers, and are not intended to provide medical advice or to substitute for the judgment of healthcare professionals in the care of their patients.

We would like to thank Rigel Pharmaceuticals for their support of the development of this Resource Page, along with a few of the resources listed within.